Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma
To determine the efficacy and safety of Chidamide combined with Duvalisib in the treatment of refractory/relapsed peripheral T-cell lymphoma.
Trial Details
- NCT ID
- NCT06151106
- Phase
- PHASE2
- Sponsor
- The First Affiliated Hospital of Xiamen University
- Status
- RECRUITING
- Cancer Type
- T-Cell Lymphoma Lymphoma
- Interventions
- Chidamide combined with Duvillisib
- Locations (sample)
- Xiamen, Fujian, China|24.47979,118.08187
Key Eligibility Criteria
- Peripheral T-cell lymphoma (PTCL) or NK/T-cell lymphoma confirmed by histopathology/cytology according to the classification standard of the World …
- Relapsed and refractory patients who have received at least first-line systemic treatment with anthracycline-containing drugs in the past. Recurren…
- There must be at least one evaluable or measurable lesion meeting Lugano2014 standard: lymph node lesion and the measurable lymph node length shoul…
- Patients aged at 18-75 years old;
For full eligibility, visit ClinicalTrials.gov.